TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03483207
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Study: NCT01744093
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice daily (BID orally) x 24 weeks
Study: NCT01744093
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice daily (BID orally) x 24 weeks
Study: NCT02148861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Study: NCT02751359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Cannabidiol
Study: NCT03535675
Drug: Muscadine Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
Study: NCT03535675
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
Study: NCT04111406
Drug: Current practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural insertion and epidural drug administration depend on anesthetist in charge
Study: NCT04111406
Drug: Protocol based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage
Study: NCT01833533
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT00158756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the Rotarix™ vaccine
Study: NCT03949244
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Study: NCT00605735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, placebo, once daily, 12 weeks
Study: NCT00343239
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days
Study: NCT02017730
Drug: [11C]BMT-136088
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01799863
Drug: Ketorolac trometamol 0.45% with carboxymethylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01799863
Drug: Preservative free artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02677181
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: short-term methotrexate
Study: NCT04534023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group
Study: NCT00166036
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 Weeks of Oral Pravastatin 80 mg therapy.
Study: NCT00127036
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
Study: NCT00127036
Drug: XELIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
Study: NCT01543191
Drug: PUR118
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose and high dose for 3 doses, BID
Study: NCT00662610
Drug: naproxen 250 mg - 500mg -750 mg bid
Normalized name: naproxen 750 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 250 mg - 500mg -750 mg bid
Study: NCT01600859
Drug: Placebo for E2609
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo
Study: NCT04281979
Drug: Study Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
Study: NCT03361345
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
Study: NCT04281979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
Study: NCT02105792
Drug: second- or third-line glucose-lowering diabetes treatment
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
Study: NCT04655872
Drug: [14C]TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
Study: NCT01836406
Drug: Ketorolac tromethamine and remote ischemic preconditioning
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
Study: NCT03560349
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study.
Study: NCT01832935
Drug: Insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
Study: NCT03028740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
Study: NCT00070057
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03058419
Drug: Caffeine 50 mg
Normalized name: caffeine 50 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study: NCT05369468
Drug: Bupivacain only
Approvals — FDA: no, EMA: no, PMDA: no
Description: to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
Study: NCT03651466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
Study: NCT02566993
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02566993
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03274882
Drug: S95005
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
Study: NCT04297995
Drug: HLX07 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 placebo 1000 mg every three weeks
Study: NCT01912638
Drug: Provisc
Normalized name: Provisc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisc is an cohesive viscoelastic.
Study: NCT00535587
Drug: Placibo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255682
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02998450
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Study: NCT01524250
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250mg of oral prednisone daily for 3 days
Study: NCT01524250
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV methylprednisolone daily for 3 days
Study: NCT02003911
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin suspension (200mg/5mL)
Study: NCT02003911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00669071
Drug: Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Study: NCT00669071
Drug: Cetaphil® Moisturizing Cream as Inactive Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Study: NCT01635062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo for 3 weeks.
Study: NCT03123861
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
Study: NCT04156620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
Study: NCT01346774
Drug: Placebo powder capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules twice a day
Study: NCT02441244
Drug: Visbiome
Normalized name: Visbiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visbiome probiotic
Study: NCT03582280
Drug: Amorphous Calcium Carbonate (ACC) - Amor
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
Study: NCT02024373
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg (every evening orally) for 8 weeks
Study: NCT01929031
Drug: ibuprofen + caffeine
Normalized name: caffeine / ergotamine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet
Study: NCT01929031
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet.
Study: NCT01929031
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet
Study: NCT01963403
Drug: EE 30mcg/LNG 150mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day; daily during study participation (up to 84 days)
Study: NCT01963403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day; daily during study participation (up to 84 days)
Study: NCT01929031
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet
Study: NCT01929031
Drug: ibuprofen + caffeine
Normalized name: caffeine / ergotamine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination (FDC) tablet
Study: NCT01929031
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03596931
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed with statins
Study: NCT01435226
Drug: placebo to match RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribovirin placebo BID
Study: NCT02394730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill taken orally once daily for 12 weeks
Study: NCT02222324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 placebo tablets matching E2609
Study: NCT01946074
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
Study: NCT01946074
Drug: ABT-165
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.
Study: NCT00507546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly 8mg of placebo (same appearance as ramelteon)
Study: NCT00145639
Drug: Ifosfamide, Carboplatin, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description for treatment plan.
Study: NCT01565616
Drug: Conditioning Regimen with Bone Marrow Transplant
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV
Study: NCT02243839
Drug: Thrombolytic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
Study: NCT02523196
Drug: HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
Study: NCT02031016
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study: NCT02031016
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study: NCT02031016
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study: NCT04019184
Drug: L-Alanyl/L-Glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
Study: NCT04019184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
Study: NCT04469621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT00809159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AIN457
Study: NCT03983252
Drug: [F-18]PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT03033836
Drug: ARV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Study: NCT00400621
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00856973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day for 12 weeks
Study: NCT00409318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC q week
Study: NCT00773734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03642353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
Study: NCT06227624
Drug: Oral zinc sulfate and standard phototherapy
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
Study: NCT02765217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
Study: NCT02328222
Drug: ESW group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
Study: NCT01880125
Drug: Tramadol HCI/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
Study: NCT00358748
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: See detailed description above.
Study: NCT00872885
Drug: GRT6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid formulation, 200 to 600 µg, single dose, one day
Study: NCT00872885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dosage
Study: NCT03161548
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14
Study: NCT00084448
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01612039
Drug: ASP3291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
Study: NCT01612039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets